一个单盲随机对照试验关于辅助认知刺激治疗对痴呆症认知结果的有效性
Soumya Bhowmik1, Mina Chandra2, Kuljeet Anand1
1Department of Neurology, ABVIMS and Dr. RML Hospital, New Delhi, India.
Annals of Indian Academy of Neurology
|August 4, 2023
概括
认知刺激疗法 (CST) 显著改善了痴呆症患者的认知功能并减少了行为症状. 这种疗法也减轻了护理人员的负担,为痴呆症护理提供了有价值的干预措施.
科学领域:
- 神经学 神经学
- 心理社会干预 心理社会干预
背景情况:
- 痴呆症是一种神经认知能力下降影响日常生活的疾病.
- 认知刺激疗法 (Cognitive Stimulation Therapy,CST) 是对痴呆症患者的一种经过验证的心理社会干预.
研究的目的:
- 评估虚拟组认知刺激疗法 (CST) 在患有重大神经认知障碍的患者中的有效性.
- 评估CST对认知功能,行为症状和护理人员负担的影响.
主要方法:
- 进行了一项单盲随机对照试验,其中50岁以上的患者被诊断患有重大神经认知障碍.
- 参与者被随机分配到一个CST组 (超过7周的14个虚拟会议) 和一个控制组 (通常的治疗).
- 认知评估包括MoCA,ADAS-Cog,神经精神病 inventory,IADL和护理人员负担 (ZBI) 在基线和8周内进行.
主要成果:
- 与对照组相比,CST组在MoCA和ADAS-Cog得分上显示出显著的改善.
- 在CST组中观察到痴呆症行为和心理症状 (BPSD) 的显著减少.
- 用ZBI测量护理人员负担,在CST组显著下降.
结论:
- 认知刺激疗法 (CST) 对痴呆症的认知结果产生了显著的积极影响.
- CST有效地管理痴呆症 (BPSD) 的行为和心理症状,并减少护理人员的负担.
相关概念视频
01:22Alzheimer's Disease: Treatment
215
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
215
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
155
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
155